# Effectiveness of free vastus lateralis musculocutaneous flap transplantation plus ultrasound-mediated transdermal Qianjin Weijing decoction for chronic empyema: a prospective, preference-based observational study

**Authors:** Fei Chen, Chao Wang, Zhihan Wang

PMC · DOI: 10.3389/fmed.2026.1780744 · Frontiers in Medicine · 2026-03-12

## TL;DR

This study finds that combining a specific surgery with a traditional Chinese medicine treatment may help reduce cavity volume in chronic empyema patients more quickly.

## Contribution

The novel contribution is the evaluation of combining free vastus lateralis musculocutaneous flap surgery with ultrasound-mediated Qianjin Weijing decoction for chronic empyema.

## Key findings

- Combined therapy reduced cavity volume more significantly at 2 weeks compared to surgery alone.
- Combined therapy led to lower procalcitonin levels at 3 months.
- No significant differences in functional or nutritional outcomes were observed.

## Abstract

To evaluate the effectiveness of free vastus lateralis musculocutaneous flap (VLMCF) transplantation combined with ultrasound-mediated delivery of Qianjin Weijing decoction for chronic empyema.

In this single-center prospective observational study (July 2023–June 2025), 114 patients elected either VLMCF surgery alone (control, n = 57) or VLMCF plus ultrasound-assisted transdermal decoction at bilateral Feishu points for 2 weeks (combined, n = 57). The primary outcome was residual cavity volume measured via 3D-CT. Secondary outcomes included nutritional, inflammatory, and quality-of-life (SF-36) markers. Analyses used ANCOVA to adjust for baseline imbalances and multiple imputation for missing data.

At 2 weeks, the combined-therapy group showed a significantly greater reduction in cavity volume compared to the control (20.52 \ ± 4.45 vs. 24.40 \ ± 6.35 mL; adjusted mean difference: −3.72 mL; 95% CI: −5.85 to −1.59; p = 0.005). By 3 months, cavity volumes were comparable. Regarding secondary outcomes, the combined group had significantly lower procalcitonin levels at 3 months (adjusted difference: −0.10; p = 0.0005). However, no robust differences were found in albumin, hemoglobin, CRP, WBC, or functional recovery (ADL/SF-36) at either time point after FDR correction.

Adding ultrasound-mediated Qianjin Weijing decoction to VLMCF transplantation may accelerate early cavity resolution and improve procalcitonin profiles in chronic empyema patients. While mid-term functional and nutritional outcomes were similar to surgery alone, the combined regimen is a safe potential adjunct. Randomized controlled trials are needed to confirm long-term benefits and causality.

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** inflammatory (MESH:D007249), chronic empyema (MESH:D004653)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017900/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13017900/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017900/full.md

---
Source: https://tomesphere.com/paper/PMC13017900